Month: August 2020

Major stocks ended up all high for three consecutive days just this first week of August. The news about reports on the coronavirus vaccine positive development and distribution plan has contributed on the promising outcome in today’s session, alongside with the expected high corporate earnings results. Another passive gain from tech giants which was led by Nasdaq hitting another record high on today’s session after reaching almost 11,000 in its trading price. Gold continuously goes up by the day at above $2000 till investors sees it as the easiest and most reliable way to save their investments. Here are the main movements in the Global Market this Wednesday; Stocks – S&P 500 jumps up with 21.24 points change or 0.64% to 3,327.75.– The Dow Jones Industrial Average climbed with 372.84 points increased or 1.39% to 27,201.31.–...

NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATESVANCOUVER, British Columbia, Aug. 07, 2020 (GLOBE NEWSWIRE) — Global Care Capital Inc. (CSE:HLTH, FRANKFURT: L6V1) (the “Company” or “Global Care”) a global investment company which engages in early stage investment opportunities in private and public companies, is pleased to announce that it has entered into a letter of intent dated August 6th, 2020 (the “LOI”), which sets out the basic terms and conditions for the acquisition by the Company of all of the issued and outstanding securities in the capital of Healthview Technologies Inc. (“Healthview”) in exchange for securities of Global Care (the “Transaction”).The Company and Healthview have entered into the LOI, which sets out certain terms and conditions pursuant to which the proposed...

LONDON, Aug. 07, 2020 (GLOBE NEWSWIRE) — OKYO (LSE:OKYO), the life sciences and biotechnology company, focused on the discovery and development of novel molecules to treat inflammatory dry eye diseases and chronic pain, is pleased to announce that it is establishing a Scientific Advisory Board which will be led by Dr A. James Khodabakhsh MD. His appointment is effectively immediately, with the remit to bring together a small group of leaders-in-the-field to review and inform the Company’s plans to progress its lead product candidate, Chemerin, to an IND in the indication of dry-eye disease.Dr. James Khodabakhsh specializes in complex surgeries of the eye and is one of the most sought after surgeons in Los Angeles and is the Medical Director at the Beverly Hills Institute of Ophthalmology.He finished his undergraduate degree at New...

Press release (MAR)Malmö, August 7, 2020Acarix AB (publ) publishes Interim Report, January – June 2020Agile and flexible with sustained focus on key prioritiesFor us and for many other companies, the pandemic and global uncertainty have caused delays in some prioritized projects. However, in combination with a dynamic Capital Market this has created a window for us to review our overall funding. The opportunity to secure funding will enable full focus with continued commercialization in priority markets and continued the research as soon as the market is normalized again.Extract from CEO Per Persson’s message to the Interim Report.Second quarter 2020 compared with same period 2019During the second quarter, four CADScor®System (5) and 660 (1,690) disposable patches were sold to end-users. In addition to these systems, six demo systems...

Press release (MAR)Malmö, 7 augusti, 2020Acarix AB (publ) publicerar delårsrapport, januari – juni 2020Adaptiva och flexibla med fokus på prioriteringarFör oss och för många andra företag har pandemin och den globala osäkerheten orsakat förseningar i vissa prioriterade projekt. I kombination med en dynamisk kapitalmarknad har detta dock skapat ett naturligt tillfälle för oss att se över vår finansiering. En säkerställd finansiering skulle möjliggöra fullt fokus på fortsatt kommersialisering på prioriterade marknader och forskning så snart marknaden har normaliserats igen.Utdrag ur VD Per Perssons kommentar till delårsrapporten.Andra kvartalet 2020 jämfört med samma period 2019Under andra kvartalet såldes fyra (5) CADScor®System och 660 (1 690) engångsplåster till slutförbrukare. Utöver dessa system såldes sex demosystem till distributörer...

Basel, Switzerland, August 07, 2020Basilea Pharmaceutica Ltd. (SIX: BSLN) announced today that the marketing authorization  application (MAA) for the antifungal isavuconazole (Cresemba®) for the treatment of patients with mucormycosis, which was submitted by Basilea’s license partner Pfizer Inc. (NYSE: PFE, “Pfizer”), has been accepted for regulatory review by the Center for Drug Evaluation at the National Medical Products Administration (NMPA) of China.David Veitch, Chief Executive Officer, said: “China is commercially a very important market for Cresemba, accounting for more than 15 percent of the global market for newer antifungals. We are therefore very pleased with the progress Pfizer is making in China, in order to address the unmet medical needs of patients suffering from invasive mold infections.”In November 2017, Basilea and...

Basel, 7. August 2020Basilea Pharmaceutica AG (SIX: BSLN) gab heute bekannt, dass der von ihrem Lizenzpartner Pfizer Inc. (NYSE: PFE, “Pfizer”) eingereichte Antrag auf Marktzulassung in China für das Antimykotikum Isavuconazol (Cresemba®) zur Behandlung von Patienten mit Mukormykose vom Center for Drug Evaluation bei der chinesischen National Medical Products Administration (NMPA) zur Prüfung angenommen wurde.David Veitch, Chief Executive Officer, sagte: „China ist für Cresemba ein kommerziell sehr wichtiger Markt und macht derzeit mehr als 15 Prozent des Weltmarkts für neuere Antimykotika aus. Wir sind daher sehr zufrieden mit den Fortschritten, die Pfizer in China macht, um die bisher nicht gedeckten medizinischen Bedürfnisse von Patienten mit invasiven Schimmelpilzinfektionen zu adressieren.“Im November 2017 erweiterten Basilea und...

On Thursday 22 October 2020 a General Meeting of Shareholders of ageas SA/NV will be organised to approve the payment of the intermediary dividend of EUR 2.38 per share.Earlier this year Ageas decided to adjust the distribution of its dividend payment of EUR 2.65 per share for the year 2019, taking into account the guidance issued by the National Bank of Belgium on 7 April 2020 in the context of COVID-19.A first dividend payment of EUR 0.27 per share was approved by the General Shareholders’ Meeting of Wednesday 20 May 2020.After careful consideration and taken into account Ageas’ strong and resilient solvency and cash position, the Ageas Board of Directors reconfirms its intention as announced on 8 April 2020, to organise a General Shareholders’ Meeting in October 2020 to approve the payment of the intermediary dividend of...

Le jeudi 22 octobre 2020, une Assemblée générale des Actionnaires d’ageas SA/NV sera organisée en vue d’approuver le paiement du dividende intermédiaire d’EUR 2,38 par action.Au début de cette année, Ageas a décidé d’ajuster la distribution de son paiement de dividende d’EUR 2,65 par action pour l’exercice 2019 compte tenu des orientations publiées par la Banque Nationale de Belgique le 7 avril 2020 dans le contexte pandémique liée au COVID-19.Un premier versement de dividende d’EUR 0,27 par action a été approuvé lors de l’Assemblée générale des Actionnaires du mercredi 20 mai 2020.Après mûre réflexion, et compte tenu de la position solide d’Ageas en matière de solvabilité et de trésorerie, le Conseil d’administration d’Ageas confirme son intention, annoncée le 8 avril 2020, d’organiser une Assemblée générale des Actionnaires en...

Op donderdag 22 oktober 2020 zal de Algemene Vergadering van Aandeelhouders van ageas SA/NV worden gehouden, ter goedkeuring van de betaling van het interim-dividend van 2,38 EUR per aandeel.Begin dit jaar beslist Ageas om de uitkering van zijn dividendbetaling van 2,65 EUR per aandeel voor het jaar 2019 aan te passen, gelet op de prognoses die de Nationale Bank van België op 7 april 2020 bekendmaakte in het kader van Covid-19.Een eerste dividendbetaling van 0,27 EUR per aandeel werd goedgekeurd door de Algemene Vergadering van Aandeelhouders van woensdag 20 mei 2020.Na grondig beraad, en gelet op de sterke en veerkrachtige solvabiliteit en cashpositie van Ageas, bevestigt de Raad van Bestuur opnieuw haar intentie die zij bekendmaakte op 8 april 2020 om een Algemene Vergadering van Aandeelhouders te organiseren in oktober 2020 ter goedkeuring...